Nkarta Q1 net loss narrows; cash seen funding to 2029

Nkarta

12/05/2026 21:11

Overview

US biotechnology firm's Q1 net loss was $27.8 mln, basic EPS at -$0.37

Cash and investments totaled $266.7 mln, expected to fund operations into 2029

Company expanded Ntrust-2 trial to include rheumatoid arthritis and enabled outpatient dosing

Outlook

Nkarta expects current cash and equivalents to fund operations into 2029

Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented in 2026

Enrollment ongoing at 4 bln cell dose level across all indications in Ntrust-1 and Ntrust-2

Result Drivers

TRIAL EXPANSION - Co expanded Ntrust-2 trial to include rheumatoid arthritis and enabled outpatient dosing to broaden patient access

ONGOING ENROLLMENT - Enrollment continues at 4 bln cell dose level across all indications in Ntrust-1 and Ntrust-2

Company press release: ID:nGNX2FY4rG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.37
Q1 Net Income
-$27.83 mln
Q1 Basic EPS
-$0.37
Q1 Cash & Investments
$266.70 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Nkarta Inc is $11.00, about 245.9% above its May 11 closing price of $3.18

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)